The relationship of cystatin C, creatinine, estimated GFR, and cardiovascular events

  • Luo Zhang (张 珞)
  • Li Ni (倪 黎)
  • Jiagao Lv (吕家高)
Article
  • 87 Downloads

Summary

This study examined the predictive value of plasma cystatin C, creatinine and estimated glomerular filtration rate (eGFR) as risk factors for cardiovascular disease in Chinese. Plasma cystatin C and creatinine were measured in 466 coronary heart disease (CHD) patients recruited from 4 hospitals and 349 healthy controls from local communities in Wuhan, China. Cockroft-Gault formula was used to estimate the glomerular filtration rate (GFR) after adjusting for body surface area. With each measure, the study population was divided into quintiles. The results showed that the patients had significantly higher levels of plasma cystatin C, creatinine, and lower level of eGFR than controls. Lower eGFR was associated with a higher risk of cardiovascular events. As compared with the first (highest) quintile, the hazard ratios (and 95% CIs) after multivariate adjustment for CHD were as follows: third quintile, 2.98 (1.54–5.78); fourth quintile, 3.34 (1.58–7.09); fifth quintile, 4.37(1.84–10.35). With higher cystatin C quintiles (≥1.00 mg/L and ≥1.17 mg/L), the hazard ratios for CHD were 2.16 (1.23–3.81) and 2.34 (1.25–4.38), similar to those of creatinine 2.21 (1.21–4.03) and 2.03 (1.07–3.84). However, it was plasma cystatin C not eGFR or creatinine had stronger association with ischemic stroke. The highest quintile had the hazard ratio of 4.51 (1.45–14.08) after multivariate adjustment. It was concluded that plasma cystatin C, associated with renal function, is not an independent risk factor for cardiovascular disease. eGFR is a better risk predictor for CHD than plasma cystatin C and creatinine. But for ischemic stroke, plasma cystatin C is a better risk factor than creatinine and estimated GFR.

Key words

coronary heart disease kidney function cystatin C stroke glomerular filtration rate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease comparison of traditional and novel risk factors. JAMA, 2005,293(14): 1737–1745CrossRefPubMedGoogle Scholar
  2. 2.
    Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation, 2007,116(1):85–97CrossRefPubMedGoogle Scholar
  3. 3.
    Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med, 2006,145(4):237–246PubMedGoogle Scholar
  4. 4.
    Johnston N, Jernberg T, Lindahl B, et al. Biochemical indicators of cardiac and renal function in a healthy elderly population. Clin Biochem, 2004,37(3):210–216CrossRefPubMedGoogle Scholar
  5. 5.
    Wasén E, Isoaho R, Mattila K, et al. Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin C. J Intern Med, 2004,256(1):70–78CrossRefPubMedGoogle Scholar
  6. 6.
    Bi ZQ, Xu H, Zhu LQ, et al. Evaluation of the clinical application of GFR-estimating equation in elderly patients. Chin J Geriatr, 2006,25(1):25–28Google Scholar
  7. 7.
    Zuo L, Ma YC, Zhou YH, et al. Application of GFR-estimating equations in Chinese patients with chronic kidney disease. Am J Kidney Dis, 2005,45:463–472CrossRefPubMedGoogle Scholar
  8. 8.
    Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med, 2005,352(20):2049–2060CrossRefPubMedGoogle Scholar
  9. 9.
    Shlipak MG, Wassel Fyr CL, Chertow GM, et al. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol, 2006, 17(1): 254–261CrossRefPubMedGoogle Scholar
  10. 10.
    Ix JH, Shlipak MG, Chertow GM, et al. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease. Circulation, 2006,115(2):173–179CrossRefPubMedGoogle Scholar
  11. 11.
    Koenig W, Twardella D, Brenner H, et al. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem, 2005,51(2):321–327CrossRefPubMedGoogle Scholar
  12. 12.
    Shlipak MG, Heidenreich PA, Noguchi H, et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med, 2002,137(7):555–562PubMedGoogle Scholar
  13. 13.
    Rule AD, Bergstralh EJ, Slezak JM, et al. Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int, 2006,69(2):399–405CrossRefPubMedGoogle Scholar
  14. 14.
    Bökenkamp A, Herget-Rosenthal S, Bökenkamp R. Cystatin C, kidney function and cardiovascular disease. Pediatr Nephrol, 2006,21(9):1223–1230CrossRefPubMedGoogle Scholar
  15. 15.
    Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med, 2004,351(13):1296–1305CrossRefPubMedGoogle Scholar
  16. 16.
    Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate. Clin Chem, 2002, 48(5):699–707PubMedGoogle Scholar
  17. 17.
    Liu J, Sukhova GK, Sun JS, et al. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol, 2004,24(8):1359–1366CrossRefPubMedGoogle Scholar
  18. 18.
    Eriksson P, Deguchi H, Samnegård A, et al. Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease. Arterioscler Thromb Vasc Biol, 2004,24(3):551–557CrossRefPubMedGoogle Scholar
  19. 19.
    Loew M, Hoffmann MM, Koenig W, et al. Genotype and plasma concentration of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events. Arterioscler Thromb Vasc Biol, 2005,25(7):1470–1474CrossRefPubMedGoogle Scholar
  20. 20.
    He Y, Chen JZ, Wang HP. Relationship between polymorphisms (rs2897119 and rs6114208) in cystatin C gene promoter region and stroke risk. Mol Cardiol China, 2007,7(4):81–84Google Scholar
  21. 21.
    Potter K, Hankey GJ, Green DJ, et al. Homocysteine or renal impairment, which is the real cardiovascular risk factor. Arterioscler Thromb Vasc Biol, 2008,28(6):1031–1033CrossRefGoogle Scholar
  22. 22.
    Luc G, Bard JM, Lesueur C, et al. Plasma cystatin C and development of coronary heart disease: the PRIME Study. Atherosclerosis, 2006,185(2):375–380CrossRefPubMedGoogle Scholar
  23. 23.
    Shlipak MG, Praught ML, Sarnak MJ. Update on cystatin C: new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens, 2006,15(3): 270–275CrossRefPubMedGoogle Scholar
  24. 24.
    Ni L, Lü J, Hou LB, et al. Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese. Stroke, 2007,38(12):3287–3288CrossRefPubMedGoogle Scholar
  25. 25.
    Ma YC, Zuo L, Wang M, et al. Comparison of MDRD equations and creatinine clearance for estimating glomerular filtration rate. J Clin Intern Med, 2006,23(1):32–35Google Scholar

Copyright information

© Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Luo Zhang (张 珞)
    • 1
  • Li Ni (倪 黎)
    • 2
  • Jiagao Lv (吕家高)
    • 2
  1. 1.Department of CardiologyCentral Hospital of XiangfanXiangfanChina
  2. 2.Department of Cardiology, Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations